Spencer Pharmaceutical(OTC) SPPH

Market Cap$300.00

Since IPO (2009)-100%

5 Year-100%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

Spencer Pharmaceutical last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-06-16

Spencer Pharmaceutical stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-02-19
1 month	+0%	USD 0.00	2026-02-19
3 month	+0%	USD 0.00	2026-02-19
Year to date	+0%	USD 0.00	2025-12-23
1 year	+0%	USD 0.00	2025-05-27
3 year	+0%	USD 0.00	2023-06-02
5 year	-99.5%	USD 0.00	2021-06-17
Since inception	-100%	USD 0.05	2009-07-30

Spencer Pharmaceutical Financials at a Glance

Market Cap

$300.00

Revenue (TTM)

$670.21K

Net Income (TTM)

-$1.24M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

12.42 (High)

Dividend

$0.00

Beta (Volatility)

12.42 (High)

Price

$0.00

Volume

3,000

Open

$0.00

Price

$0.00

Volume

3,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

12.42 (High)

Price

$0.00

Volume

3,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

SPPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spencer Pharmaceutical

Spencer Pharmaceutical Inc. is focused on developing innovative drug delivery platforms for neurological conditions. The company specializes in the controlled administration of therapeutic compounds for disorders such as Alzheimer's and Parkinson's disease, as well as brain cancer. Additionally, Spencer Pharmaceutical has a proprietary slow-release drug delivery system for managing type-2 diabetes and arthritis.

Products and Services

Drug delivery systems for neurological disorders
Proprietary slow-release system for diabetes and arthritis
Research and development in central nervous system therapies

Growth Outlook

Established in 1998, with a strong foundation in drug delivery technology
Expanding research into additional therapeutic applications
Potential market growth driven by increasing neurological disorder prevalence

Financial Highlights

Recent quarterly revenue of 670,214, showing operational activity
Trailing twelve months (TTM) net income reflects ongoing investment in R&D
Current ratio of 0.79 indicates liquidity management

Spencer Pharmaceutical Inc. operates primarily in North America and Europe, with its headquarters located in Boston, Massachusetts. The company has a dedicated focus on addressing significant medical needs through innovative solutions. The recent quarterly revenue indicates that the company is actively engaged in its operations, while the TTM net income highlights the ongoing investment in research and development. The current ratio suggests a careful approach to liquidity, which is essential for sustaining operations and funding future growth initiatives. As the prevalence of neurological disorders continues to rise, Spencer Pharmaceutical is well-positioned to capitalize on emerging opportunities in the pharmaceutical market.

AI Generated • Aug 5, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Boston, MA 02109, US

SPPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-50.17%

Return on Capital

21.49%

Return on Assets

-20.35%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.00

Shares Outstanding

294.36M

Volume

3.00K

Avg. Volume

47.619

Financials (TTM)

Gross Profit

$90.08K

Operating Income

$1.33M

EBITDA

-$1.30M

Operating Cash Flow

-$635.30K

Capital Expenditure

$0.00

Free Cash Flow

-$635.30K

Cash & ST Invst.

$2.83K

Total Debt

$541.45K

Spencer Pharmaceutical Performance Analysis

Spencer Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2003-06-30	N/A
Q3	2003-09-30	N/A
Q4	2003-12-31	N/A
Q1	2004-03-31	N/A

Spencer Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2003-06-30	N/A
Q3	2003-09-30	64.8%
Q4	2003-12-31	-468.2%
Q1	2004-03-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2004YOY CHG

Revenue

$670.21K

N/A

Gross Profit

$90.08K

N/A

Gross Margin

13.44%

N/A

Market Cap

$300.00

N/A

Market Cap/Employee

$150.00

N/A

Employees

N/A

Net Income

-$509.69K

-278.1%

EBITDA

-$460.66K

-250.8%

Quarterly Fundamentals

Name

Q1 2004YOY CHG

Total Cash

$2.83K

-96.8%

Total Debt

$541.45K

N/A

Accounts Receivable

$644.38K

+214693.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$541.45K

N/A

Return on Assets

-20.35%

N/A

Return on Invested Capital

22.35%

N/A

Free Cash Flow

-$82.67K

+61.9%

Operating Cash Flow

-$82.67K

+61.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OPGXOptigenex Inc.

OPGXOptigenex Inc.$0.00+0.00%

IPAHInterpharm Holdings, Inc.

IPAHInterpharm Holdings, Inc.$0.00+0.00%

PXYNPraxsyn Corporation

PXYNPraxsyn Corporation$0.00+0.00%

MHTXManhattan Scientifics, Inc.

MHTXManhattan Scientifics, Inc.$0.00+0.00%

BIOIFBiome Grow Inc.

BIOIFBiome Grow Inc.$0.00+0.00%

CBGLCannabis Global Inc.

CBGLCannabis Global Inc.$0.00+0.00%

IMMBImmunotech Laboratories, Inc.

IMMBImmunotech Laboratories, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About SPPH

What is the current price of Spencer Pharmaceutical?

Spencer Pharmaceutical is trading at $0.00 per share.

What is the 52-week range for Spencer Pharmaceutical?

Over the past 52 weeks, Spencer Pharmaceutical has traded between $0.00 and $0.00.

How much debt does Spencer Pharmaceutical have?

Spencer Pharmaceutical total debt is unavailable.

How much cash does Spencer Pharmaceutical have on hand?

Spencer Pharmaceutical does not have cash on hand data available.

What is Spencer Pharmaceutical’s dividend yield?

Spencer Pharmaceutical does not currently have a dividend yield.

Spencer Pharmaceutical(OTC) SPPH

Spencer Pharmaceutical Financials at a Glance

SPPH News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Spencer Pharmaceutical

SPPH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Spencer Pharmaceutical Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SPPH

What is the current price of Spencer Pharmaceutical?

What is the 52-week range for Spencer Pharmaceutical?

How much debt does Spencer Pharmaceutical have?

How much cash does Spencer Pharmaceutical have on hand?

What is Spencer Pharmaceutical’s dividend yield?

Premium Investing Services